Replimune Group Inc. Company Profile
NASDAQ: REPLHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
Pre-market: 13.23 +0.23%
Replimune Group at a glance
Replimune Group Inc. (NASDAQ: REPL) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in Woburn, MA. Replimune Group is led by Dr. Sushil Patel Ph.D. and employs about 465 people. The company's shares have traded publicly since 2018.
At a market capitalization of $1.25 billion, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001737953, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Replimune Group do?
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that expresses an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4. The company was founded in 2015 and is headquartered in Woburn, Massachusetts.
Business description based on the company's public filings.
Company information
- Legal name
- Replimune Group Inc.
- Ticker
- NASDAQ: REPL
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Sushil Patel Ph.D.
- Employees
- 465
- Headquarters
- 500 Unicorn Park Drive, Woburn, MA, United States
- Phone
- 781 222 9600
- Website
- replimune.com
- IPO year
- 2018
- Market cap
- $1.25B
- SEC CIK
- 0001737953
- Latest annual report
- 10-K · Jun 29, 2026
Companies similar to Replimune Group
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| COAGHemab Therapeutics Holdings Inc. | 28.70 | +1.16% | $1.34B | vs REPL |
| IMTXImmatics N.V. | 7.45 | -0.67% | $1.13B | vs REPL |
| INBXInhibrx Biosciences Inc. | 93.36 | -0.05% | $1.37B | vs REPL |
| VORVor Biopharma Inc. | 18.78 | +2.57% | $1.11B | vs REPL |
| TSHATaysha Gene Therapies Inc. | 4.43 | +0.91% | $1.44B | vs REPL |
| MGTXMeiraGTx Holdings plc | 10.82 | +2.08% | $1.04B | vs REPL |
| MAZEMaze Therapeutics Inc. | 26.25 | -0.68% | $1.46B | vs REPL |
| IMCRImmunocore Holdings plc ADR | 29.41 | -0.47% | $1.51B | vs REPL |